# Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Source: https://onco.cc/trials/nct05887492/  
OnCo record `nct05887492` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Tango Therapeutics, Inc., active and no longer recruiting.

## Summary

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors is a phase 1/2 interventional study registered as NCT05887492 by Tango Therapeutics, Inc., with 126 participants planned, started 2023-06-12 and due to reach its primary completion in 2026-09. Interventions recorded: TNG260, Pembrolizumab. Conditions listed: Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05887492
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors
- Sponsor: Tango Therapeutics, Inc.
- Enrolled: 126

## Sources

- ClinicalTrials.gov NCT05887492: https://clinicaltrials.gov/study/NCT05887492

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [TNG260](https://onco.cc/drugs/tng260/)
- companies: [Tango Therapeutics](https://onco.cc/companies/tango-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05887492.json